The fate of abortion care: Will the Supreme Court limit access to mifepristone?

Published Updated 4 Min Read

A woman holding a sign that says, "Protect safe and legal abortions" outside on a street lined with green trees. Only the sign is in focus.
Adobe Stock

Over 20 years since the FDA approved the commonly used abortion pill mifepristone, its safety is being put into question before the Supreme Court — and the verdict could result in a nationwide end to abortion care as we know it.

According to the Guttmacher Institute, 63% of abortions were done through pills like mifepristone and misoprostol in 2023. These two pills, often used together, can terminate an early pregnancy without surgery. Less than 1% of women have gone to the hospital due to adverse effects from mifepristone, and the FDA saw fit to expand access to the pill in 2016 and 2021. However, the anti-abortion group Alliance for Hippocratic Medicine (AHM) argues that the use of mifepristone harms healthcare providers, and as a result, the FDA was wrong to expand access. 

Deanna Cuadra
Senior Reporter

Deanna Cuadra is a senior reporter at Employee Benefit News. Her work covers healthcare, U.S. policy and reform, challenges faced by women and parents in the workplace and innovation in work culture … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form